Pleasanton and Redwood City, CA
21 April 2015
AstraZeneca will use Bina’s Genomic Management Solution platform to accelerate the incorporation of genomic data into its drug development programs across three main therapeutic areas.
Bina Technologies, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) , and AstraZeneca (NYSE: AZN) today announced that they have entered into a collaborative agreement . As part of the agreement, AstraZeneca will be the first member to join the Bina Alliance Program and gain roadmap influence to develop the Bina Genomic Management Solution (GMS)1. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.
Bina’s proprietary Bina GMS enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop Bina GMS for pharmaceutical applications.
Bina GMS is a powerful data analysis platform that will help AstraZeneca more effectively leverage genomic data across our global organization and more rapidly develop personalized and effective therapies to treat complex diseases, said Dr. Carl Barrett, Vice President, Translational Oncology, at AstraZeneca. We believe our foundational collaboration with Bina will significantly accelerate the incorporation of genomic data into all phases of drug development.
Justin Johnson, Principal Translational Genomic Scientist at AstraZeneca, added: In working with Bina, we can not only significantly accelerate the speed in which we incorporate genomic data into areas like target discovery and patient selection, but we can do this on top of a flexible, scalable and validated analysis infrastructure that our bench scientists can work with. Johnson will be presenting early results of the collaboration during the Cambridge Healthtech Institute’s 14th Annual Bio-IT World Conference and Expo (Bio-IT) in Boston, MA on Thursday 23 April.
We are very excited about the work we are doing with the AstraZeneca team, said Dr. Narges Bani Asadi, CEO and Founder of Bina. In this collaboration, our multidisciplinary team of scientists and engineers will try to push the boundaries of genomics research. We are very fortunate to be able to contribute to the research at AstraZeneca. Through this collaboration we both hope to define a new standard for the pharmaceutical research industry in how to effectively leverage the genomic information for discovery and development.
For more information on the Bina Alliance Program, please contact [email protected] Academic researchers please visit the Bina Research Grant Program.
About Bina Technologies
Bina Technologies builds next-generation technologies for scalable, accurate processing and management of genomic information. Bina’s Genomic Management Solution is a comprehensive analysis platform used by clinical and translational researchers to gain insight from their genomic data sets. Bina’s Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalized medicine. Bina Technologies was acquired by Roche in December, 2014. Learn more about Bina’s product, technologies, and team at www.bina.com.
1 Bina products are for research use only and not for use in diagnostic procedures.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Bina Technologies Media Enquiries
Kena Hudson or Rachel Wallace
Chempetitive Group for Bina
Roche Sequencing Media Enquiries
Head of Corporate Communications
Phone: +1 520.468.9145
Email: Jacquie Bucher
Esra Erkal-Paler, +44 20 7604 8030
Ayesha Bharmal, +44 20 7604 8034